___

• 1. Dahlberg M, Glimelius B, Påhlman L. Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial, AnnSurg. 1999;229(4):493-7.
• 2. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24):5644-50.
• 3. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T et al Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638-46.
• 4. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, el al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excisionfor rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group studyJ Clin Oncol. 2005;23(25):6199-206.
• 5. Roh MS, Colangelo L, Wieand S. Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum. In: 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, J ClinOncol 2004:246.
• 6. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
• 7. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124-30.
• 8. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J ClinOncol 2006;24:4620-5.
• 9. Bosset JF, Collette L, Calais G. EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23.
• 10. Bujko K, Nowacki MP, Nasierowska-Guttmejer A. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomized trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004;72:15-24.
• 11. Bujko K, Nowacki MP, Kepka L. Polish Colorectal Study Group. Postoperative complications in patients irradiated pre-operatively for rectal cancer: report of a randomized trial comparing short-term radiotherapy vs. chemoradiation. Colorectal Dis 2005;7:410-6.
• 12. Ngan S, Fisher R, Goldstein D. A randomized trial comparing local recurrence (LR) rates between short course (SC) and long course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS). In: 46th Annual Meeting of the American Society of Clinical Oncology June 04-08, 2004, Chicago, IL, J ClinOncol2010:28.
• 13. Lefevre JH, Rousseau A, Svrcek M, Parc Y, Simon T, Tiret E; French Research Group of Rectal Cancer Surgery (GRECCAR) A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemo therapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design. BMC Cancer. 2013;13:417.
• 14. Sloothaak DA, Geijsen DE, vanLeersum NJ, Punt CJ, Buskens CJ, Bemelman WA, et al. Optimal time interval between neoadjuvant chemoradio therapy and surgery for rectal cancer. Br J Surg. 2013;100(7):933-9.
• 15. Probst CP, Becerra AZ, Aquina CT, Tejani MA, Wexner SD, Garcia-Aguilar J, et al. Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation. J Am Coll Surg. 2015;221(2):430-40.